Pro-Cure Therapeutics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pro-Cure Therapeutics Ltd. - overview
Established
2001
Location
York, -, UK
Primary Industry
Pharmaceuticals
About
Pro-Cure Therapeutics Ltd. is a biotechnology firm focusing on developing innovative therapies for cancer treatment, utilizing proprietary technologies to enhance patient care and outcomes. Pro-Cure Therapeutics Ltd. specializes in innovative cancer therapies, having been founded in 2001 in York, UK.
The company raised GBP 720,000 in venture funding on December 2, 2009, with contributions from Maven VCT, YFM Equity Partners, and Yorkshire Cancer Research. The firm has engaged in two investment deals, and its current valuation stands at GBP 6. 73 mn. Pro-Cure Therapeutics Ltd.
is dedicated to advancing cancer treatment solutions through proprietary technology aimed at improving therapeutic effectiveness. They focus on developing treatment protocols that target specific cancer types, utilizing advanced research methodologies to create therapies that enhance patient survival rates and quality of life. Their offerings are tailored for healthcare providers and research institutions worldwide, fostering collaboration to elevate cancer care standards. In the most recent year, Pro-Cure Therapeutics Ltd.
reported revenue of GBP 280,944. 2 with an EBITDA of GBP -540,693. 3, reflecting the ongoing investments in research and development for their therapeutic solutions. Pro-Cure Therapeutics Ltd.
plans to bolster its growth by launching new therapies aimed at specific cancer types in the coming years. The firm intends to expand its market presence into North America and parts of Asia by 2025, leveraging recent funding of GBP 720,000 to support these initiatives. This funding will facilitate the further development and commercialization of their innovative cancer treatments, ensuring the company can effectively reach new healthcare providers and patients globally.
Current Investors
White Rose Technology Seedcorn Fund, Yorkshire Cancer Research, YFM Equity Partners
Primary Industry
Pharmaceuticals
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.pro-cure.uk.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Pro-Cure Therapeutics Ltd. - financials
| Fiscal Year Ended | Jul 31, 2004 | Jul 31, 2005 | Jul 31, 2006 | Apr 30, 2007 | Apr 30, 2008 |
|---|---|---|---|---|---|
| Revenue (USD) | 37,435 | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | (186,814) | - | - | - | - |
| Operating Income (USD) | (192,978) | - | - | - | - |
| Operating Margin | (515.5%) | - | - | - | - |
| % EBITDA Margin | (499.0%) | - | - | - | - |
| NET Income (USD) | (192,179) | - | - | - | - |
| % Net Margin | (513.4%) | - | - | - | - |
Pro-Cure Therapeutics Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.